- [...] curved nitroxide derivative and its preparation method and application (by machine translation)
-
The invention discloses a sand-kouba curved nitroxide derivatives, have the formula I shown in the chemical structure of: Also discloses the sand kouba curved nitrooxyderivatives pharmaceutically acceptable salts or its pharmaceutically acceptable solvates. Also discloses a pharmaceutical composition, comprising a pharmaceutically-acceptable carrier, a pharmaceutically effective amount of the nitroxide derivatives [...] curved and/or its salt or stereoisomers. Also disclosed sand kouba curved nitrooxyderivatives of the preparation method, and [...] curved nitroxide derivatives or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof in the preparation of a medicament for treating cardiovascular diseases in the application. (by machine translation)
- -
-
Paragraph 0067; 0069
(2019/01/06)
-
- NITRIC OXIDE RELEASING PROSTAGLANDIN DERIVATIVES FOR TREATING NORMAL TENSION GLAUCOMA
-
This invention provides a method of lowering intraocular pressure in a patient having normal tension glaucoma, comprising contacting an eye of a subject having normal tension glaucoma with a pharmaceutical composition comprising an effective amount of Nitric Oxide releasing prostaglandin derivatives of formula (I).
- -
-
Page/Page column 13; 14
(2018/05/27)
-
- NITROXY DERIVATIVES OF SOFT STEROIDS
-
A compound of formula (I) or a pharmaceutically acceptable salt thereof, and an ophthalmic composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof. The invention is also directed to the use of the ophthalmic compositions for treating inflammatory conditions of the palpebral or bulbar conjunctiva, cornea and anterior segment of the globe, and to ameliorate inflammation associated with corneal injury.
- -
-
Page/Page column 17
(2013/09/26)
-
- NITRATE ESTERS OF CARBONIC ANHYDRASE INHIBITORS
-
Nitroderivatives of carbonic anhydrase inhibitors having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma, ocular hypertension, age-related macular degeneration, diabetic macular edema, diabetic retinopathy, hypertensive retinopathy and retinal vasculopathies, cancer, epilepsy, high-altitude disorders and neuromuscular diseases.
- -
-
Page/Page column 64
(2008/12/06)
-
- PROSTAGLANDIN DERIVATIVES
-
Nitroderivatives of prostaglandin amides having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
- -
-
Page/Page column 59
(2008/06/13)
-
- FLUOROPROSTAGLANDINS NITRODERIVATIVES
-
Nitroderivatives of fluoroprostaglandins having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
- -
-
Page/Page column 34-35
(2008/06/13)
-
- Nitric oxide enhancing diuretic compounds, compositions and methods of use
-
The invention describes novel compositions and kits comprising at least one nitric oxide enhancing diuretic compound, or pharmaceutically acceptable salts thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating conditions resulting from excessive water and/or electrolyte retention; (b) treating cardiovascular diseases; (c) treating renovascular diseases; (d) treating diabetes; (e) treating diseases resulting from oxidative stress; (f) treating endothelial dysfunctions; (g) treating diseases caused by endothelial dysfunctions; (h) treating cirrhosis; (j) treating pre-eclampsia; (k) treating osteoporosis; (l) treating nephropathy; (m) treating peripheral vascular diseases; (n) treating portal hypertension; (o) treating central nervous system disorders; (p) treating metabolic syndrome; (q) treating sexual dysfunctions; and (r) hyperlipidemia. The nitric oxide enhancing diuretic compounds comprise at least one nitric oxide enhancing group linked to the diuretic compound through one or more sites such as carbon, oxygen and/or nitrogen via a bond or moiety that cannot be hydrolyzed.
- -
-
Page/Page column 50
(2008/06/13)
-
- PROCESS FOR PREPARING HALOGENOALKYLNITRATES
-
A process for preparing a compound of formula (I) X-(CH2)n-ONO2 (I) wherein: X is a halogen atom selected from Cl, Br, I; n is an integer from 3 to 6; said process comprising the slow addition of a compound of formula (II)
- -
-
Page/Page column 4-5
(2008/06/13)
-
- PROSTAGLANDIN NITROOXYDERIVATIVES
-
Prostaglandin nitrooxyderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
- -
-
Page/Page column 36
(2008/06/13)
-
- PROCESS FOR PREPARING NITROOXYALKYL SUBSTITUTED ESTERS OF CARBOXYLIC ACIDS, INTERMEDIATES USEFUL IN SAID PROCESS AND PREPARATION THEREOF
-
The present invention refers to a process for preparing a compound of general formula (A), as reported in the description, wherein R is a radical of a drug and R1-R12 are hydrogen or alkyl groups, m, n, o, q, r and s are each independently an integer from
- -
-
-
- PROCESS FOR PREPARING NITROOXYDERIVATIVES OF NAPROXEN
-
The present invention refers to a process for preparing a compound of general formula (A), wherein R is a radical of naproxen or bromonaproxen and R1-R12 are hydrogen or alkyl groups, m, n, o, q, r and s are each independently an integer from 0 to 6, and p is 0 or 1, and X is O, S, SO, SO2, NR13 or PR13or an aryl, heteroaryl group, said process comprising reacting a compound of formula (B) : R-COOZ wherein R is as defined above and Z is hydrogen or a cation selected from: Li+, Na+, K+, Ca++, Mg++, tetralkylammonium, tetralkylphosphonium, with a compound of formula (C), as reported in the description, wherein R1-R12 and m, n, o, p, q, r, s are as defined above and Y is a suitable leaving group.
- -
-
-
- Syntheses, Calcium Channel Agonist-Antagonist Modulation Activities, and Nitric Oxide Release Studies of Nitrooxyalkyl 1,4-Dihydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl) pyridine-5-carboxylate Racemates, Enantiomers, and Diastereomers
-
A novel group of hybrid calcium channel (CC) modulators was prepared where the isopropyl ester moiety of isopropyl 1,4-dlhydro-2,6-dimethyl-3-nitro-4-(2,1,3-benzoxadiazol-4-yl) pyridine-5-carboxylate (PN 202-791) was replaced by a variety of nitric oxide
- Shan, Rudong,Velazquez, Carlos,Knaus, Edward E.
-
p. 254 - 261
(2007/10/03)
-
- Synthesis and Pharmacological Evaluation of (Nitrooxy)alkyl Apovincaminates
-
A series of (nitrooxy)alkyl apovincaminates has been synthesized and evaluated for their effects on vertebral and femoral blood flow.These derivatives were prepared from apovincaminic acid (4).In cerebral circulation, compound 5 (0.03-1.0 mg/kg iv) caused a dose-dependent increase in cerebral blood flow (CerBF) without affecting the blood pressure.It was more potent than vinpocetine (2).The structures of 2 and 5, determined by X-ray crystallography, showed differences in the electrostatic potential image and in the conformation of the ethyl group at the 16-position.
- Kawashima, Yutaka,Ikemoto, Tomoyuki,Horiguchi, Akiyo,Hayashi, Masatoshi,Matsumoto, Keita,et al.
-
p. 815 - 819
(2007/10/02)
-
- Synthesis and antihypertensive activities of new 1,4-dihydropyridine derivatives containing nitrooxyalkylester moieties at the 3- and 5-positions
-
We have synthesized new 1,4-dihydropyridine derivatives having nitrooxyalkylester moieties at the 3- and 5-positions in order to develop potent and long-lasting vasodilators. The antihypertensive activities of these compounds were compared with that of nifedipine. One of them, 2- nitrooxypropyl 3-nitrooxypropyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydro- 3,5-pyridinedicarboxylate (CD-349) was selected for further development. The structure-activity relationship is discussed.
- Ogawa,Nakazato,Tsuchida,Hatayama
-
p. 1049 - 1054
(2007/10/02)
-